Cargando…

Cardiovascular tissue banking in Europe

INTRODUCTION: In the past 50 years, human cardiovascular tissue allografts, also called homografts, have been implanted into patients with different valvular diseases. The use of these allografts and  the number of cardiovascular tissue banks and their respective techniques increased. We conducted a...

Descripción completa

Detalles Bibliográficos
Autores principales: de By, T M M H, Parker, R, Delmo Walter, E M, Hetzer, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: EDIMES Edizioni Internazionali Srl 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563559/
https://www.ncbi.nlm.nih.gov/pubmed/23439733
_version_ 1782258212285710336
author de By, T M M H
Parker, R
Delmo Walter, E M
Hetzer, R
author_facet de By, T M M H
Parker, R
Delmo Walter, E M
Hetzer, R
author_sort de By, T M M H
collection PubMed
description INTRODUCTION: In the past 50 years, human cardiovascular tissue allografts, also called homografts, have been implanted into patients with different valvular diseases. The use of these allografts and  the number of cardiovascular tissue banks and their respective techniques increased. We conducted a survey to establish the quantity of allografts processed, and issued by, European tissue banks. The survey also included the collection of other relevant statistics. METHODS: In 2011, the Foundation of European Tissue Banks collected data from 19 different cardiovascular tissue banks in 11 European countries. RESULTS: From  2007 to 2010 the  data show a decrease in the number of hearts received, from 1700 to 1640 in 18 tissue banks; the average number of hearts received for cardiovascular tissue processing decreased from 113 to 91. The number of heart valves issued for transplantation increased from 1272 in 2007 to 1486 in 2010. The average rate of discard because of microbiological contamination was 20.7%, while 4.2% of the grafts were not used because of positive serology. Half of the tissue banks issued arterial grafts, while 3 banks also issued veins and pericardium. An overview of decontamination methods shows considerable methodological differencesbetween 17 cardiovascular tissue banks. CONCLUSIONS: From the experience in Europe, it can be concluded that cardiovascular tissue banks have an established place in the domain of cardiovascular surgery. The statistics show fluctuating data concerning the demand for human cardiovascular allografts and methodological questions. There is room for growth and improvement with respect to validation of decontamination methods.
format Online
Article
Text
id pubmed-3563559
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher EDIMES Edizioni Internazionali Srl
record_format MEDLINE/PubMed
spelling pubmed-35635592013-02-25 Cardiovascular tissue banking in Europe de By, T M M H Parker, R Delmo Walter, E M Hetzer, R HSR Proc Intensive Care Cardiovasc Anesth Research-Article INTRODUCTION: In the past 50 years, human cardiovascular tissue allografts, also called homografts, have been implanted into patients with different valvular diseases. The use of these allografts and  the number of cardiovascular tissue banks and their respective techniques increased. We conducted a survey to establish the quantity of allografts processed, and issued by, European tissue banks. The survey also included the collection of other relevant statistics. METHODS: In 2011, the Foundation of European Tissue Banks collected data from 19 different cardiovascular tissue banks in 11 European countries. RESULTS: From  2007 to 2010 the  data show a decrease in the number of hearts received, from 1700 to 1640 in 18 tissue banks; the average number of hearts received for cardiovascular tissue processing decreased from 113 to 91. The number of heart valves issued for transplantation increased from 1272 in 2007 to 1486 in 2010. The average rate of discard because of microbiological contamination was 20.7%, while 4.2% of the grafts were not used because of positive serology. Half of the tissue banks issued arterial grafts, while 3 banks also issued veins and pericardium. An overview of decontamination methods shows considerable methodological differencesbetween 17 cardiovascular tissue banks. CONCLUSIONS: From the experience in Europe, it can be concluded that cardiovascular tissue banks have an established place in the domain of cardiovascular surgery. The statistics show fluctuating data concerning the demand for human cardiovascular allografts and methodological questions. There is room for growth and improvement with respect to validation of decontamination methods. EDIMES Edizioni Internazionali Srl 2012 /pmc/articles/PMC3563559/ /pubmed/23439733 Text en Copyright © 2012, HSR Proceedings in Intensive Care and Cardiovascular Anesthesia http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License 3.0, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/3.0/ and http://creativecommons.org/licenses/by-nc/3.0/legalcode.
spellingShingle Research-Article
de By, T M M H
Parker, R
Delmo Walter, E M
Hetzer, R
Cardiovascular tissue banking in Europe
title Cardiovascular tissue banking in Europe
title_full Cardiovascular tissue banking in Europe
title_fullStr Cardiovascular tissue banking in Europe
title_full_unstemmed Cardiovascular tissue banking in Europe
title_short Cardiovascular tissue banking in Europe
title_sort cardiovascular tissue banking in europe
topic Research-Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563559/
https://www.ncbi.nlm.nih.gov/pubmed/23439733
work_keys_str_mv AT debytmmh cardiovasculartissuebankingineurope
AT parkerr cardiovasculartissuebankingineurope
AT delmowalterem cardiovasculartissuebankingineurope
AT hetzerr cardiovasculartissuebankingineurope